当前位置: X-MOL 学术Indian J. Hematol. Blood Transfus. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study
Indian Journal of Hematology and Blood Transfusion ( IF 0.9 ) Pub Date : 2021-04-12 , DOI: 10.1007/s12288-021-01433-w
Liangliang Ren 1 , Ling Li 1 , Lei Zhang 1 , Xin Li 1 , Xiaorui Fu 1 , Xinhua Wang 1 , Jingjing Wu 1 , Zhenchang Sun 1 , Xiaoyan Feng 1 , Yu Chang 1 , Zhiyuan Zhou 1 , Feifei Nan 1 , Jiaqin Yan 1 , Fei Kong 1 , Mingzhi Zhang 1
Affiliation  

Limited treatment options are available for relapsed or refractory diffuse large B cell lymphoma (RR DLBCL). Few clinical studies have reported the use of Ibrutinib, a covalent Bruton Tyrosine kinase (BTK) inhibitor, in RR DLBCL. There are relatively few clinical studies about Ibrutinib in RR DLBCL now. We retrospectively investigated the safety and efficacy of Ibrutinib (alone or in combination with other drugs) in patients with RR DLBCL. We reviewed the medical records of 40 RR DLBCL patients who received Ibrutinib alone or in combination with other drugs in our hospital from June 2018 to August 2020. The objective response rate (ORR) of RR DLBCL patients on Ibrutinib was 22.5%. The median progression free survival time (PFS) was 13.0 months (95% CI 8.914–17.086), and the median overall survival time (OS) was 15.0 months (95% CI 11.931–18.089). Rash (25.0%) and fatigue (25.0%) were the most common adverse reactions in this study. The application of Ibrutinib to patients with RR DLBCL has good short-term efficacy, and the adverse reactions are well tolerated. Combined treatment of Ibrutinib with other drugs has been found to more effective than Ibrutinib therapy alone.



中文翻译:

依鲁替尼治疗复发或难治性弥漫性大 B 细胞淋巴瘤:一项回顾性研究

复发或难治性弥漫性大 B 细胞淋巴瘤 (RR DLBCL) 的治疗选择有限。很少有临床研究报告在 RR DLBCL 中使用共价布鲁顿酪氨酸激酶 (BTK) 抑制剂依鲁替尼。目前关于依鲁替尼治疗 RR DLBCL 的临床研究相对较少。我们回顾性研究了依鲁替尼(单独或与其他药物联合)在 RR DLBCL 患者中的安全性和有效性。我们回顾了2018年6月至2020年8月在我院接受依鲁替尼单药或联合其他药物治疗的40例RR DLBCL患者的病历。RR DLBCL患者对依鲁替尼的客观缓解率(ORR)为22.5%。中位无进展生存时间 (PFS) 为 13.0 个月 (95% CI 8.914–17.086),中位总生存时间 (OS) 为 15.0 个月 (95% CI 11.931–18.089)。皮疹 (25.0%) 和疲劳 (25.0%) 是本研究中最常见的不良反应。依鲁替尼应用于RR DLBCL患者短期疗效好,不良反应耐受性良好。已发现依鲁替尼与其他药物的联合治疗比单独使用依鲁替尼治疗更有效。

更新日期:2021-04-12
down
wechat
bug